HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 4776人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308509, encodeId=e61c130850969, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, objectType=article, longId=139112, objectId=33c3139112e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33c3139112e3, replyNumber=0, likeNumber=50, createdTime=2018-05-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33c3139112e3, moduleTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33c3139112e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308508, encodeId=ff5c1308508f8, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, objectType=article, longId=136871, objectId=94111368e1b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94111368e1b3, replyNumber=0, likeNumber=67, createdTime=2018-05-01, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94111368e1b3, moduleTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94111368e1b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308507, encodeId=9852130850ed8, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌性脑膜炎患者鞘内注射曲妥珠单抗的可行性研究, objectType=article, longId=136866, objectId=9bc413686612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bc413686612, replyNumber=0, likeNumber=68, createdTime=2018-05-01, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bc413686612, moduleTitle=HER2阳性乳腺癌性脑膜炎患者鞘内注射曲妥珠单抗的可行性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bc413686612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308506, encodeId=a7cc13085069f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=殷咏梅教授：晚期HER2阳性乳腺癌治疗之“三生三世”, objectType=article, longId=136315, objectId=605d1363159f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=605d1363159f, replyNumber=0, likeNumber=53, createdTime=2018-04-26, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=605d1363159f, moduleTitle=殷咏梅教授：晚期HER2阳性乳腺癌治疗之“三生三世”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=605d1363159f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308505, encodeId=2469130850587, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析, objectType=article, longId=132605, objectId=9efd13260523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9efd13260523, replyNumber=0, likeNumber=0, createdTime=2018-03-18, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9efd13260523, moduleTitle=JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9efd13260523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308504, encodeId=eed91308504ca, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Her2阳性乳腺癌的靶向治疗--曲妥珠单抗, objectType=article, longId=130228, objectId=82b6130228f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82b6130228f5, replyNumber=0, likeNumber=64, createdTime=2018-02-22, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82b6130228f5, moduleTitle=Her2阳性乳腺癌的靶向治疗--曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82b6130228f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308503, encodeId=4e371308503b1, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet oncol：双重封闭HER2联合环磷酰胺治疗HER2阳性的转移性乳腺癌患者的效果评估, objectType=article, longId=129583, objectId=27e712958339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27e712958339, replyNumber=0, likeNumber=129, createdTime=2018-02-12, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27e712958339, moduleTitle=Lancet oncol：双重封闭HER2联合环磷酰胺治疗HER2阳性的转移性乳腺癌患者的效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27e712958339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308502, encodeId=d02a1308502c3, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。, objectType=article, longId=126038, objectId=58561260389d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58561260389d, replyNumber=0, likeNumber=133, createdTime=2018-01-11, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58561260389d, moduleTitle=Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58561260389d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308501, encodeId=bb7413085012e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, objectType=article, longId=124477, objectId=e6f71244e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f71244e794, replyNumber=0, likeNumber=62, createdTime=2017-12-26, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f71244e794, moduleTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f71244e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308500, encodeId=8d6e1308500af, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=CLIN CANCER RES：HER2阳性乳腺癌T-DM1获得性耐药与Cyclin B1诱导缺陷, objectType=article, longId=121645, objectId=aec1121645ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aec1121645ac, replyNumber=0, likeNumber=66, createdTime=2017-11-30, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aec1121645ac, moduleTitle=CLIN CANCER RES：HER2阳性乳腺癌T-DM1获得性耐药与Cyclin B1诱导缺陷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aec1121645ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308499, encodeId=f918130849932, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。, objectType=article, longId=121373, objectId=6a6c1213e360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a6c1213e360, replyNumber=0, likeNumber=54, createdTime=2017-11-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a6c1213e360, moduleTitle=Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a6c1213e360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308498, encodeId=078e1308498a4, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=[ABC4圆桌会] HER2阳性晚期乳腺癌：以抗HER2为基础，从一线到维持治疗, objectType=article, longId=119835, objectId=da0c1198353d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da0c1198353d, replyNumber=0, likeNumber=63, createdTime=2017-11-15, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da0c1198353d, moduleTitle=[ABC4圆桌会] HER2阳性晚期乳腺癌：以抗HER2为基础，从一线到维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da0c1198353d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308497, encodeId=7ee0130849ee4, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=[ABC4]徐兵河教授：HER2阳性晚期乳腺癌治疗的“变”与“不变”, objectType=article, longId=119222, objectId=de27119222d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de27119222d0, replyNumber=0, likeNumber=70, createdTime=2017-11-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de27119222d0, moduleTitle=[ABC4]徐兵河教授：HER2阳性晚期乳腺癌治疗的“变”与“不变”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de27119222d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308496, encodeId=f402130849613, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌治愈是否指日可待？, objectType=article, longId=117115, objectId=cb3011e115fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3011e115fd, replyNumber=0, likeNumber=68, createdTime=2017-10-23, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3011e115fd, moduleTitle=HER2阳性乳腺癌治愈是否指日可待？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb3011e115fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308495, encodeId=399513084954d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=【CSCO 2017】把握驱动，精准治疗—— 江泽飞教授谈HER2阳性乳腺癌治疗现状, objectType=article, longId=115047, objectId=c8a211504e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8a211504e83, replyNumber=0, likeNumber=63, createdTime=2017-10-03, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8a211504e83, moduleTitle=【CSCO 2017】把握驱动，精准治疗—— 江泽飞教授谈HER2阳性乳腺癌治疗现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8a211504e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308494, encodeId=b1ec13084945b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JAMA：细胞毒性肿瘤浸润淋巴细胞在转移性HER2阳性乳腺癌预后预测中的作用, objectType=article, longId=107539, objectId=6cea10e53915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cea10e53915, replyNumber=0, likeNumber=53, createdTime=2017-08-04, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cea10e53915, moduleTitle=JAMA：细胞毒性肿瘤浸润淋巴细胞在转移性HER2阳性乳腺癌预后预测中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cea10e53915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308493, encodeId=06411308493c0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM ：帕妥珠单抗辅助曲妥珠单抗和化疗可改善HER2阳性早期乳腺癌患者的预后！, objectType=article, longId=106025, objectId=664e1060250f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=664e1060250f, replyNumber=0, likeNumber=67, createdTime=2017-07-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=664e1060250f, moduleTitle=NEJM ：帕妥珠单抗辅助曲妥珠单抗和化疗可改善HER2阳性早期乳腺癌患者的预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=664e1060250f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308492, encodeId=8933130849247, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM:双靶方案适用于早期Her2阳性乳腺癌的辅助治疗吗？, objectType=article, longId=105946, objectId=811e10594668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811e10594668, replyNumber=0, likeNumber=0, createdTime=2017-07-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811e10594668, moduleTitle=NEJM:双靶方案适用于早期Her2阳性乳腺癌的辅助治疗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=811e10594668)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308491, encodeId=44181308491d0, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=CLIN CANCER RES：DC疫苗可以增强免疫反应及诱导HER2阳性DCIS病情缓解, objectType=article, longId=104301, objectId=ad3c10430157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad3c10430157, replyNumber=0, likeNumber=76, createdTime=2017-07-03, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad3c10430157, moduleTitle=CLIN CANCER RES：DC疫苗可以增强免疫反应及诱导HER2阳性DCIS病情缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad3c10430157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308490, encodeId=50c11308490b6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, objectType=article, longId=99073, objectId=0118990e3ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0118990e3ca, replyNumber=0, likeNumber=69, createdTime=2017-05-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0118990e3ca, moduleTitle=JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0118990e3ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果

2018-05-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活

2018-05-01

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌性脑膜炎患者鞘内注射曲妥珠单抗的可行性研究

2018-05-01

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

殷咏梅教授：晚期HER2阳性乳腺癌治疗之“三生三世”

2018-04-26

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析

2018-03-18

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Her2阳性乳腺癌的靶向治疗--曲妥珠单抗

2018-02-22

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet oncol：双重封闭HER2联合环磷酰胺治疗HER2阳性的转移性乳腺癌患者的效果评估

2018-02-12

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet oncol：曲妥单抗、帕妥珠单抗、帕博西尼和氟维司群联合治疗HER2阳性、ER阳性的乳腺癌患者的效果和安全性。

2018-01-11

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌

2017-12-26

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

CLIN CANCER RES：HER2阳性乳腺癌T-DM1获得性耐药与Cyclin B1诱导缺陷

2017-11-30

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。

2017-11-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

[ABC4圆桌会] HER2阳性晚期乳腺癌：以抗HER2为基础，从一线到维持治疗

2017-11-15

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

[ABC4]徐兵河教授：HER2阳性晚期乳腺癌治疗的“变”与“不变”

2017-11-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌治愈是否指日可待？

2017-10-23

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

【CSCO 2017】把握驱动，精准治疗—— 江泽飞教授谈HER2阳性乳腺癌治疗现状

2017-10-03

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JAMA：细胞毒性肿瘤浸润淋巴细胞在转移性HER2阳性乳腺癌预后预测中的作用

2017-08-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM ：帕妥珠单抗辅助曲妥珠单抗和化疗可改善HER2阳性早期乳腺癌患者的预后！

2017-07-21

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM:双靶方案适用于早期Her2阳性乳腺癌的辅助治疗吗？

2017-07-20

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

CLIN CANCER RES：DC疫苗可以增强免疫反应及诱导HER2阳性DCIS病情缓解

2017-07-03

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：Pyrotinib治疗HER2阳性转移性乳腺癌Ⅰ期临床试验结果

2017-05-20

科室
- - 订阅+
  - 更多科室
工具
服务